CA
SNDX icon

CoreCap Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

CoreCap Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$146K Buy
+5,723
New +$133K 0.01% 611

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

CoreCap Advisors's SNDX Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Syndax Pharmaceuticals (SNDX) in Q4 2022: 5,723 shares worth $146K. The stake represents 0.01% of the portfolio and ranks #611 among its holdings.

160 funds tracked by Wall St. Rank hold SNDX as of Q4 2022.

  • CoreCap Advisors held 5,723 shares of Syndax Pharmaceuticals worth $146K as of Q4 2022.
  • Syndax Pharmaceuticals was a new CoreCap Advisors position in Q4 2022.
  • Syndax Pharmaceuticals made up 0.01% of CoreCap Advisors's portfolio in Q4 2022, its #611 holding.
  • 160 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.